Brexit and H4R

The H4R Consortium is monitoring Brexit’s potential impact on both registrants of H4R substances in the UK and on registrants outside of the UK who import substances registered with H4R dossiers into the UK. It is H4R’s preference to ensure a smooth transition and avoid additional data access fees for companies that already paid H4R for data access in connection with REACH.

However, the relevant arrangements and rules are still unknown. Any changes to H4R’s Terms and Conditions for Data Access will need to be agreed by the H4R Executive Committee once the position is clear. This may include changes to the licensing agreements with third parties and a consideration of the administrative costs that may need to be passed on if revised documentation is required.

H4R will publicise these changes when known.

If you have any questions in the meantime, please contact us through